FCF jumped to $23.1m on debtor release while ROE slipped to 3.3%

That uplift was largely funded by a NZ$4.9m drop in trade debtors to NZ$12.8m (-27.8%), which pushed debtor days to 9.0 — the lower edge of the supplied historical range (mean 12.7 days). Net debt roughly halved to NZ$5.7m and cash on hand rose 56.4% to NZ$28.9m.

Underlying earnings moved less. Revenue grew 3.9% to NZ$259.9m, operating profit (EBIT) was up 7.8% to NZ$16.1m, PBT rose 5.7% to NZ$11.1m, and NPAT was 0.0% at NZ$5.6m. ROE eased to 3.3% from 3.4%, sitting below the historical baseline of 4.7%. A 2.5 cps interim dividend was declared.

• Pre-lease FCF/NPAT of 408.7% is flattering because it reflects a working-capital release rather than a step-change in earnings. Operating working capital fell NZ$3.7m and capex was cut 31.2% to NZ$2.2m (0.8% of revenue). This matters because the deleveraging — net debt down NZ$7.3m — is partly a one-time benefit; if debtor days normalise back toward the 12.7-day mean, a meaningful slice of the OCF gain reverses.
• Returns are running below the recent baseline. ROE at 3.3% sits below the historical range of 3.4%–6.8%, NPAT margin of 2.2% is at the lower bound of the 2.2%–3.2% range, and PBT margin of 4.3% sits at the lower edge of 4.2%–6.0%. Modest top-line growth is not yet translating into stronger profitability, which limits the read-through from the headline cash improvement.
• Mix shift toward Medical services. Medical services revenue grew 13.2% to NZ$77.7m (29.9% of group, up 2.4pp), with derived margin of 10.6% versus Pharmacy services at 4.9%. Pharmacy revenue was effectively flat at NZ$182.2m. This matters because the higher-margin segment is doing the work, while the larger segment is barely growing.

The available shape context shows HY24 contributed 49.6% of FY24 revenue and 47.7% of FY24 NPAT, indicating a modestly second-half-weighted pattern; annualising HY25 revenue gives roughly NZ$519.8m, broadly above FY24's NZ$503.9m if the same shape holds. The release does not anchor a margin trajectory, so whether the 2H builds on HY25's PBT growth or fades back toward the lower margin baseline cannot be judged from this filing.

The 7.8% lift in EBIT did not flow through to NPAT because the effective tax rate held essentially flat at 27.2% (vs 27.1%) — there is no tax distortion here, and PBT is the cleaner read.

Cash quality is weaker than it looks. The bulk of the cash improvement reflects (a) a NZ$4.9m receivables release that took debtor days to the lower edge of the historical range and (b) a NZ$1.0m capex step-down. Neither is structural earnings growth. The 2.5 cps dividend is comfortably covered by FCF pre-lease (15.6% payout) but takes 63.6% of NPAT, so dividend cover at the earnings line is tight if either the receivables benefit or the capex restraint reverses. Note that the HY24 comparable included a discontinued operation contributing NZ$4.3m of prior-period profit, which is why the like-for-like NPAT is presented attributable-to-shareholders rather than total profit.

This briefing cannot assess whether the working-capital release reflects a structural collection improvement or a timing benefit that will unwind in 2H25.